BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
Number Citing Articles
1 Eames JR, Tran B. Hepatitis C. Physician Assistant Clinics 2021;6:555-68. [DOI: 10.1016/j.cpha.2021.05.002] [Reference Citation Analysis]
2 Adnane S, Mahad C, Haitami S, Ben Yahya I. Hepatitis C virus infection and oral lichen planus: A controversial association. Advances in Oral and Maxillofacial Surgery 2022;6:100271. [DOI: 10.1016/j.adoms.2022.100271] [Reference Citation Analysis]
3 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
4 Van Pilsum Rasmussen SE, Seaman S, Brown D, Desai N, Sulkowski M, Segev DL, Durand CM, Sugarman J. Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. AJOB Empir Bioeth 2020;11:40-52. [PMID: 31618112 DOI: 10.1080/23294515.2019.1670277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Kind J, Maeschli B, Bruggmann P. How to set the agenda for hepatitis C: a theory-driven policy analysis. Health Res Policy Syst 2022;20:20. [PMID: 35164777 DOI: 10.1186/s12961-022-00824-3] [Reference Citation Analysis]
6 Facente SN, Patel S, Hecht J, Wilson E, McFarland W, Page K, Vickerman P, Fraser H, Burk K, Morris MD. Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs. Clin Infect Dis 2021;73:e1290-5. [PMID: 33768236 DOI: 10.1093/cid/ciab261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dussaq AM, Soni A, Willey C, Park SL, Harada S. Hepatitis C Virus Genie: A Web 2.0 Interpretation and Analytics Platform for the Versant Hepatitis C Virus Genotype Line Probe Assay Version 2.0. J Pathol Inform 2017;8:41. [PMID: 29114435 DOI: 10.4103/jpi.jpi_44_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Chin J, Reyes AC, Chen C, Over A, Hsu E, Rich S, Lomiguen C. Undergraduate Medical School Health Fair Hepatitis Screenings: Utilizing Non-Profit Community Organizations. Int J Prev Med 2021;12:93. [PMID: 34584658 DOI: 10.4103/ijpvm.IJPVM_68_20] [Reference Citation Analysis]
9 Gostin LO, Monahan JT, Kaldor J, DeBartolo M, Friedman EA, Gottschalk K, Kim SC, Alwan A, Binagwaho A, Burci GL, Cabal L, DeLand K, Evans TG, Goosby E, Hossain S, Koh H, Ooms G, Roses Periago M, Uprimny R, Yamin AE. The legal determinants of health: harnessing the power of law for global health and sustainable development. Lancet 2019;393:1857-910. [PMID: 31053306 DOI: 10.1016/S0140-6736(19)30233-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 22] [Article Influence: 23.3] [Reference Citation Analysis]
10 Vega TA, Levander XA, Seaman A, Korthuis PT, Englander H. "Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. J Subst Abuse Treat 2021;127:108337. [PMID: 34134860 DOI: 10.1016/j.jsat.2021.108337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li C, Liang J, Xiang H, Chen H, Tian J. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine (Baltimore) 2020;99:e23384. [PMID: 33235113 DOI: 10.1097/MD.0000000000023384] [Reference Citation Analysis]
12 Teaima MH, Al-Nuseirat A, Abouhussein D, Badary OA, El-Nabarawi MA. Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study. J Pharm Policy Pract 2021;14:106. [PMID: 34915937 DOI: 10.1186/s40545-021-00389-6] [Reference Citation Analysis]
13 Valle-Millares D, Brochado-Kith Ó, Gómez-Sanz A, Martín-Carbonero L, Ryan P, De Los Santos I, Castro JM, Troya J, Mayoral-Muñoz M, Cuevas G, Martínez-Román P, Sanz-Sanz J, Muñoz-Muñoz M, Jiménez-Sousa MÁ, Resino S, Briz V, Fernández-Rodríguez A; multidisciplinary Group of viral coinfection HIV/Hepatitis (COVIHEP). HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization. Biomed Pharmacother 2021;145:112405. [PMID: 34781145 DOI: 10.1016/j.biopha.2021.112405] [Reference Citation Analysis]
14 Wong WW, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A, Feng Z, Feld JJ, Mitsakakis N, Powis J, Krahn M. Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. Value in Health 2022;25:247-56. [DOI: 10.1016/j.jval.2021.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Aunins TR, Marsh KA, Subramanya G, Uprichard SL, Perelson AS, Chatterjee A. Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms. J Virol 2018;92:e02098-17. [PMID: 29563295 DOI: 10.1128/JVI.02098-17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zullig LL, Bhatia HL, Gellad ZF, Eatherly M, Henderson R, Bosworth HB. Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. BMC Health Serv Res 2019;19:521. [PMID: 31345218 DOI: 10.1186/s12913-019-4349-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Green V, Roytman M, Komatsu H. Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review. Case Reports in Hepatology 2022;2022:1-5. [DOI: 10.1155/2022/3556780] [Reference Citation Analysis]
18 Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y. Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infect Dis Ther 2019;8:285-99. [PMID: 30771220 DOI: 10.1007/s40121-019-0234-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther 2018;47:1023-31. [PMID: 29377245 DOI: 10.1111/apt.14527] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
20 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Forde KA, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd. The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. PLoS One 2021;16:e0258143. [PMID: 34610030 DOI: 10.1371/journal.pone.0258143] [Reference Citation Analysis]
21 Wang H, Fang Y, He W, Chen R, Chen S. Clinical Trials with External Control: Beyond Propensity Score Matching. Stat Biosci. [DOI: 10.1007/s12561-022-09341-x] [Reference Citation Analysis]
22 Crowley D, Murtagh R, Cullen W, Lambert JS, McHugh T, Van Hout MC. Hepatitis C virus infection in Irish drug users and prisoners - a scoping review. BMC Infect Dis 2019;19:702. [PMID: 31395032 DOI: 10.1186/s12879-019-4218-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
23 Facente SN, Grebe E, Burk K, Morris MD, Murphy EL, Mirzazadeh A, Smith AA, Sanchez MA, Evans JL, Nishimura A, Raymond HF; End Hep C SF. Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination. PLoS One 2018;13:e0195575. [PMID: 29641546 DOI: 10.1371/journal.pone.0195575] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
24 Kakuda TN, McClure MW, Westland C, Vuong J, Homery MC, Poizat G, Viguerie L, Denot C, Patat A, Zhang Q, Hui J, Apelian D, Smith DB, Chanda SM, Fry J. Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. Pharmacol Res Perspect 2018;6:e00395. [PMID: 29736243 DOI: 10.1002/prp2.395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Villani R, Di Cosimo F, Romano AD, Sangineto M, Serviddio G. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Sci Rep 2021;11:13944. [PMID: 34230541 DOI: 10.1038/s41598-021-93251-3] [Reference Citation Analysis]
26 Facente SN, Grinstein R, Broussard J, Shost J, Azari S, Siruno J, Jimenez JA, Luetkemeyer AF, Burk K. Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action. Public Health Rep. [DOI: 10.1177/00333549221083741] [Reference Citation Analysis]
27 Gorin JB, Malone DFG, Strunz B, Carlsson T, Aleman S, Björkström NK, Falconer K, Sandberg JK. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. Sci Rep 2020;10:2081. [PMID: 32034167 DOI: 10.1038/s41598-020-58768-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
28 Kulkeaw K, Pengsart W. Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases. Micromachines (Basel) 2021;12:842. [PMID: 34357252 DOI: 10.3390/mi12070842] [Reference Citation Analysis]
29 Marathe G, Moodie EEM, Brouillette M, Cox J, Delaunay CL, Cooper C, Hull M, Gill J, Walmsley S, Pick N, Klein MB; Canadian Co-Infection Cohort. Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada. Antiviral Therapy 2022;27:135965352110676. [DOI: 10.1177/13596535211067610] [Reference Citation Analysis]
30 Klein K, Nelson J, Long C, Speeg K, Alkhouri N, Hall R. Effect of Hepatitis C Viremia on Posttransplant Diabetes Mellitus in Liver Transplant Recipients. Prog Transplant 2021;:15269248211064879. [PMID: 34874192 DOI: 10.1177/15269248211064879] [Reference Citation Analysis]
31 Jha MK, Trivedi MH. Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. Int J Mol Sci 2018;19:E233. [PMID: 29329256 DOI: 10.3390/ijms19010233] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
32 Hashim A, Almahdi F, Albaba EA, Barkia O, Alkasam R, Almahmoud A, Nabil A, Alsulaimani A, Mosli M. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia. J Epidemiol Glob Health 2020;10:178-83. [PMID: 32538035 DOI: 10.2991/jegh.k.200117.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]